Mereo BioPharma (MREO) Non Operating Income (2023)

Mereo BioPharma (MREO) reported Non Operating Income of -$4000.0 for Q4 2023, up 33.33% quarter-over-quarter from -$6000.0 in Q1 2023.

Mereo BioPharma (MREO) Non Operating Income (2023) Analysis & Trends

Mereo BioPharma (MREO) has 1 years of Non Operating Income data on file, last reported at -$4000.0 in Q4 2023.

  • Non Operating Income for Q4 2023 came in at -$4000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2024 was -$4000.0 (changed N/A YoY), and the FY2025 annual result was $300000.0, changed N/A from the prior year.
  • Non Operating Income grew to -$4000.0 in Q4 2023 per MREO's latest filing, from -$6000.0 in the prior quarter.
  • Over five years, Non Operating Income peaked at -$4000.0 in Q4 2023 and troughed at -$6000.0 in Q1 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Op. Inc. (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - 5.75 Mn
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - 444,000.00
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - 9.35 Mn
10 Mereo BioPharma 252.49 Mn 252.49 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2023 -4,000.00
Mar 31, 2023 -6,000.00